IDEAYA Biosciences(IDYA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IDYA IDEAYA Biosciences

盘前交易 02-12 04:15:11 EST

31.90

-1.35

-4.06%

最高33.55	最低31.12	成交量101.40万
今开33.39	昨收33.25	日振幅7.31%
总市值27.97亿	流通市值26.10亿	总股本8,767万
成交额3,253万	换手率1.24%	流通股本8,182万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IDYA","market":"US","secType":"STK","nameCN":"IDEAYA Biosciences","latestPrice":31.9,"timestamp":1770843600000,"preClose":33.25,"halted":0,"volume":1014027,"delay":0,"changeRate":-0.04060150375939854,"floatShares":81816082,"shares":87666408,"eps":-1.822728,"marketStatus":"盘前交易","change":-1.35,"latestTime":"02-12 04:15:11 EST","open":33.39,"high":33.55,"low":31.12,"amount":32525318.593719,"amplitude":0.073083,"askPrice":36.36,"askSize":100,"bidPrice":12.76,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.822728,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770906600000},"marketStatusCode":1,"adr":0,"listingDate":1558584000000,"exchange":"NASDAQ","adjPreClose":31.9,"postHourTrading":{"tag":"盘后","latestPrice":31.9,"preClose":31.9,"latestTime":"16:53 EST","volume":17001,"amount":542350.2,"timestamp":1770846839669,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.135193971715912,"impliedVol":1.4051,"impliedVolPercentile":0.988},"requestUrl":"/m/hq/s/IDYA","defaultTab":"news","newsList":[{"id":"2608718758","title":"IDEAYA生物科学盘中异动 早盘快速拉升5.03%报33.81美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608718758","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608718758?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:58","pubTimestamp":1770044325,"startTime":"0","endTime":"0","summary":"北京时间2026年02月02日22时58分，IDEAYA生物科学股票出现波动，股价快速拉升5.03%。截至发稿，该股报33.81美元/股，成交量9.1298万股，换手率0.10%，振幅5.03%。IDEAYA生物科学股票所在的生物技术行业中，整体涨幅为0.83%。IDEAYA生物科学公司简介：IDEAYA Biosciences Inc是一家专注于肿瘤学的精准医学公司，致力于发现和开发针对通过分子诊断选择的患者群体的靶向治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202225845a6cac68e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202225845a6cac68e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IDYA","PARG","BK4023","BK4139"],"gpt_icon":0},{"id":"1179251871","title":"IDEAYA Biosciences 在第44届摩根大通医疗健康大会上公布业务进展及2026年企业目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1179251871","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179251871?lang=zh_cn&edition=full","pubTime":"2026-01-12 01:01","pubTimestamp":1768150874,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences 于第44届摩根大通医疗健康大会期间，向外界披露了公司最新业务动态。此次更新涵盖了研发管线进展、战略合作态势等关键运营领域。同时，管理层清晰阐述了面向2026年的企业战略目标，为长期发展勾勒出明确路线图。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"gpt_icon":0},{"id":"1166503731","title":"IDEAYA Biosciences完成了一项针对HLA*A2阴性转移性眼黑色素瘤的达罗伐赛替尼与克唑替尼联合治疗的随机关键2/3期试验（Optimum-02）的全面目标入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1166503731","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166503731?lang=zh_cn&edition=full","pubTime":"2025-12-11 19:01","pubTimestamp":1765450873,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences完成了一项针对HLA*A2阴性转移性眼黑色素瘤的达罗伐赛替尼与克唑替尼联合治疗的随机关键2/3期试验（Optimum-02）的全面目标入组。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"gpt_icon":0},{"id":"1184302088","title":"IDEAYA Biosciences 提交 Ide574 的 IND 申请，成为潜在的首个 Kat6/7 双重抑制剂，用于治疗乳腺癌和肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1184302088","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184302088?lang=zh_cn&edition=full","pubTime":"2025-12-10 19:01","pubTimestamp":1765364472,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences 提交 Ide574 的 IND 申请，成为潜在的首个 Kat6/7 双重抑制剂，用于治疗乳腺癌和肺癌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"gpt_icon":0},{"id":"1195525161","title":"IDEAYA Biosciences：12月4日，格拉克索史克终止与IDEAYA Biosciences的合作协议 - SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1195525161","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195525161?lang=zh_cn&edition=full","pubTime":"2025-12-06 05:24","pubTimestamp":1764969853,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences：12月4日，格拉克索史克终止与IDEAYA Biosciences的合作协议 - SEC备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"gpt_icon":0},{"id":"1152170018","title":"IDEAYA Biosciences宣布获得Ide034的IND批准，成为首个针对多种实体肿瘤类型的双特异性B7h3/Ptk7 Top1抗体药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1152170018","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152170018?lang=zh_cn&edition=full","pubTime":"2025-12-01 19:02","pubTimestamp":1764586929,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences宣布获得Ide034的IND批准，这是一款潜在的首个针对多种实体肿瘤类型的双特异性B7h3/Ptk7 Top1抗体药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"gpt_icon":0},{"id":"1153173463","title":"IDEAYA Biosciences Inc - 截至9月30日拥有约11.4亿美元现金、现金等价物和可出售证券；预计将支持运营至2030年","url":"https://stock-news.laohu8.com/highlight/detail?id=1153173463","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153173463?lang=zh_cn&edition=full","pubTime":"2025-11-04 19:09","pubTimestamp":1762254554,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences Inc - 截至9月30日拥有约11.4亿美元现金、现金等价物和可出售证券；预计将支持运营至2030年","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"gpt_icon":0},{"id":"1172465068","title":"IDEAYA Biosciences股价上涨2.3%，因其药物组合在罕见眼癌试验中显示生存获益","url":"https://stock-news.laohu8.com/highlight/detail?id=1172465068","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172465068?lang=zh_cn&edition=full","pubTime":"2025-10-20 21:33","pubTimestamp":1760967191,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences股价上涨2.3%，因其药物组合在罕见眼癌试验中显示生存获益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"gpt_icon":0},{"id":"1166166740","title":"IDEAYA Biosciences Inc - 达罗伐西尼与克唑替尼组合展现21.1个月的中位总生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1166166740","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166166740?lang=zh_cn&edition=full","pubTime":"2025-10-20 18:01","pubTimestamp":1760954488,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences Inc - 达罗伐西尼与克唑替尼组合展现21.1个月的中位总生存期","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"gpt_icon":0},{"id":"1168936080","title":"IDEAYA Biosciences宣布其潜在首创Mat2a抑制剂Ide397与Trodelvy®联合治疗Mtap缺失尿路上皮癌的1/2期试验获得积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1168936080","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168936080?lang=zh_cn&edition=full","pubTime":"2025-09-08 20:01","pubTimestamp":1757332875,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences宣布其潜在首创Mat2a抑制剂Ide397与Trodelvy®联合治疗Mtap缺失尿路上皮癌的1/2期试验获得积极数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"gpt_icon":0},{"id":"1128114189","title":"IDEAYA Biosciences宣布Ide397与Trodelvy®联合治疗Mtap缺失非小细胞肺癌的1/2期试验首位患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1128114189","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128114189?lang=zh_cn&edition=full","pubTime":"2025-09-04 18:02","pubTimestamp":1756980132,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences近日宣布，其Ide397（一种潜在的首创Mat2a抑制剂）与Trodelvy®联合用于治疗Mtap缺失非小细胞肺癌的1/2期组合试验已完成首位患者入组。\n这项临床试验标志着IDEAYA Biosciences在开发针对特定基因缺失患者群体的创新治疗方案方面迈出了重要一步。Ide397作为一种潜在的首创Mat2a抑制剂，与Trodelvy®的联合应用有望为Mtap缺失的非小细胞肺癌患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"gpt_icon":0},{"id":"1184389741","title":"IDEAYA Biosciences宣布提交Ide892的IND申请，该药物为针对MTAP缺失实体瘤的潜在同类最佳PRMT5抑制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1184389741","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184389741?lang=zh_cn&edition=full","pubTime":"2025-09-03 18:03","pubTimestamp":1756893790,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences宣布提交Ide892的IND申请，该药物为针对MTAP缺失实体瘤的潜在同类最佳PRMT5抑制剂","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"gpt_icon":0},{"id":"2558850641","title":"高盛最新研报以“2Q25 EPS更新”为主题其中重点对Amylyx(AMLX.US)、CG Oncology(CGON.","url":"https://stock-news.laohu8.com/highlight/detail?id=2558850641","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558850641?lang=zh_cn&edition=full","pubTime":"2025-08-12 19:17","pubTimestamp":1754997464,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4135","LU1868836591.USD","LU0251131958.USD","LU0048573561.USD","LU2237443549.SGD","IE00B19Z3B42.SGD","LU2471134796.USD","BK4533","LU2750360641.GBP","LU1668664300.SGD","LU1868836757.USD","LU2237443895.HKD","LU1868837300.USD","IE00B64PRP62.GBP","LU2471134952.CNY","BK4585","LU1894683348.USD","LU2237443622.USD","IE00BFXG1179.USD","IE00BSNM7G36.USD","LU0061475181.USD","CGON","LU0742534661.SGD","IE00BGHQF748.EUR","CG","159399","BK4516","BK4552","IE0004086264.USD","BK4550","LU1868836914.USD","AMLX","LU2471134879.HKD","GPCR","LU2237438978.USD","IDYA","LU1868837136.USD","BK4599","LU0096364046.USD","BK4139","BK4127","IE00B3QW5Z07.USD","BK4504","LU2237443978.SGD","LU2237443465.HKD","LU2750360997.AUD","IE00B19Z3581.USD","159837","IE0004091025.USD"],"gpt_icon":0},{"id":"2558684301","title":"IDEAYA生物科学2025财年第二财季实现净利润-77.49百万美元，同比减少46.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558684301","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558684301?lang=zh_cn&edition=full","pubTime":"2025-08-11 00:00","pubTimestamp":1754841645,"startTime":"0","endTime":"0","summary":"8月11日，IDEAYA生物科学公布财报，公告显示公司2025财年第二财季净利润为-77.49百万美元，同比减少46.84%；其中营业收入为0.00美元，每股基本收益为-0.88美元。从资产负债表来看，IDEAYA生物科学总负债81.62百万美元，其中短期债务318000.00美元，资产负债比为0.13，流动比率为0.13。机构评级：截至2025年8月11日，当前有14家机构对IDEAYA生物科学目标价做出预测，其中目标均价为46.43美元，其中最低目标价为25.00美元，最高目标价为72.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000127a4805627&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000127a4805627&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IDYA"],"gpt_icon":0},{"id":"2557956492","title":"IDEAYA生物科学盘中异动 早盘快速跳水5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557956492","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557956492?lang=zh_cn&edition=full","pubTime":"2025-08-07 22:18","pubTimestamp":1754576334,"startTime":"0","endTime":"0","summary":"北京时间2025年08月07日22时18分，IDEAYA生物科学股票出现波动，股价快速下跌5.08%。截至发稿，该股报22.43美元/股，成交量7.6509万股，换手率0.09%，振幅6.83%。IDEAYA生物科学股票所在的生物技术行业中，整体跌幅为0.28%。IDEAYA生物科学公司简介：IDEAYA Biosciences Inc是一家专注于肿瘤学的精准医学公司，致力于发现和开发针对通过分子诊断选择的患者群体的靶向治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807221855a47b3811&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807221855a47b3811&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PARG","BK4023","IDYA","BK4139"],"gpt_icon":0},{"id":"2518127182","title":"IDEAYA生物科学盘中异动 股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518127182","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518127182?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:55","pubTimestamp":1741618519,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时55分，IDEAYA生物科学股票出现异动，股价急速跳水5.04%。截至发稿，该股报17.53美元/股，成交量15.5541万股，换手率0.18%，振幅4.71%。IDEAYA生物科学股票所在的生物技术行业中，整体涨幅为0.27%。IDEAYA生物科学公司简介：IDEAYA Biosciences Inc是一家专注于肿瘤学的精准医学公司，致力于发现和开发针对通过分子诊断选择的患者群体的靶向治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022551998a2b17b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022551998a2b17b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PARG","BK4139","BK4023","IDYA"],"gpt_icon":0},{"id":"2516668860","title":"IDEAYA生物科学盘中异动 股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516668860","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516668860?lang=zh_cn&edition=full","pubTime":"2025-03-04 03:55","pubTimestamp":1741031723,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日03时55分，IDEAYA生物科学股票出现波动，股价大幅跳水5.06%。截至发稿，该股报19.53美元/股，成交量36.3073万股，换手率0.41%，振幅7.06%。IDEAYA生物科学股票所在的生物技术行业中，整体涨幅为0.41%。IDEAYA生物科学公司简介：IDEAYA Biosciences Inc是一家专注于肿瘤学的精准医学公司，致力于发现和开发针对通过分子诊断选择的患者群体的靶向治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304035523abe68cbd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304035523abe68cbd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4023","IDYA","BK4139","PARG"],"gpt_icon":0},{"id":"2512464751","title":"IDEAYA生物科学2024财年实现净利润-2.74亿美元，同比减少142.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512464751","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512464751?lang=zh_cn&edition=full","pubTime":"2025-02-20 12:01","pubTimestamp":1740024073,"startTime":"0","endTime":"0","summary":"2月20日，IDEAYA生物科学公布财报，公告显示公司2024财年净利润为-2.74亿美元，同比减少142.48%；其中营业收入为7.00百万美元，同比减少70.07%，每股基本收益为-3.36美元。从资产负债表来看，IDEAYA生物科学总负债64.94百万美元，其中短期债务298000.00美元，资产负债比为0.18，流动比率为0.15。机构评级：截至2025年2月20日，当前有12家机构对IDEAYA生物科学目标价做出预测，其中目标均价为50.92美元，其中最低目标价为27.00美元，最高目标价为62.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220120114abd5a403&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220120114abd5a403&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IDYA"],"gpt_icon":0},{"id":"2511826524","title":"IDEAYA生物科学盘中异动 股价大跌5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511826524","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511826524?lang=zh_cn&edition=full","pubTime":"2025-02-13 23:26","pubTimestamp":1739460407,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日23时26分，IDEAYA生物科学股票出现波动，股价大幅下跌5.15%。截至发稿，该股报20.82美元/股，成交量14.152万股，换手率0.16%，振幅4.56%。IDEAYA生物科学股票所在的生物技术行业中，整体涨幅为0.15%。IDEAYA生物科学公司简介：IDEAYA Biosciences Inc 是一家专注于肿瘤学的精准医疗公司，致力于发现和开发针对患者群体的靶向治疗方法，使用分子诊断方法进行选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213232647a244b74d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213232647a244b74d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IDYA","BK4139"],"gpt_icon":0},{"id":"1172724045","title":"IDEAYA Biosciences 2024年第四季度GAAP每股亏损$(1.49)，低于预期$(0.64)，销售额$700万高于预期$467万","url":"https://stock-news.laohu8.com/highlight/detail?id=1172724045","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172724045?lang=zh_cn&edition=full","pubTime":"2025-02-13 19:10","pubTimestamp":1739445025,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences报告季度每股亏损$，低于分析师一致预期的$，差距为132.81%。公司报告季度销售额为$700万，高于分析师一致预期的$467万，超出50.00%。相比去年同期的$392万，销售额增长了78.43%。以上内容来自Benzinga Earnings专栏，原文如下：$IDEAYA Biosciences$  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 132.81 percent. This is a 186.54 percent decrease over losses of $ per share from the same period last year.  The company reported quarterly sales of $7.00 million which beat the analyst consensus estimate of $4.67 million by 50.00 perc","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"IDEAYA Biosciences 2024年第四季度GAAP每股亏损$(1.49)，低于预期$(0.64)，销售额$700万高于预期$467万","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ideayabio.com","stockEarnings":[{"period":"1week","weight":-0.0415},{"period":"1month","weight":-0.1341},{"period":"3month","weight":0.0025},{"period":"6month","weight":0.3111},{"period":"1year","weight":0.492},{"period":"ytd","weight":-0.0772}],"compareEarnings":[{"period":"1week","weight":0.0084},{"period":"1month","weight":-0.0046},{"period":"3month","weight":0.0296},{"period":"6month","weight":0.0754},{"period":"1year","weight":0.1431},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"IDEAYA Biosciences, Inc.总部位于加利福尼亚州南旧金山，于2015年6月在特拉华州注册成立。该公司是一家专注于肿瘤学的精准医学公司，致力于为使用分子诊断选择的患者群体发现和开发靶向疗法。他们的方法将识别和验证翻译生物标志物的广泛能力与小分子药物发现相结合，以选择最有可能从他们正在开发的靶向治疗中受益的患者群体。他们正在将这些能力应用于多类精准医学，包括直接靶向致癌途径和合成致死性，这代表了一类新兴的精准医学靶点。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.019424},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.057268},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.129256},{"month":4,"riseRate":0.5,"avgChangeRate":0.093972},{"month":5,"riseRate":0.5,"avgChangeRate":0.174201},{"month":6,"riseRate":0.714286,"avgChangeRate":0.088034},{"month":7,"riseRate":0.571429,"avgChangeRate":0.026528},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.032458},{"month":9,"riseRate":0.714286,"avgChangeRate":0.113335},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.051627},{"month":11,"riseRate":0.857143,"avgChangeRate":0.118123},{"month":12,"riseRate":0.571429,"avgChangeRate":0.016661}],"exchange":"NASDAQ","name":"IDEAYA Biosciences","nameEN":"IDEAYA Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"IDEAYA Biosciences(IDYA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供IDEAYA Biosciences(IDYA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"IDEAYA Biosciences,IDYA,IDEAYA Biosciences股票,IDEAYA Biosciences股票老虎,IDEAYA Biosciences股票老虎国际,IDEAYA Biosciences行情,IDEAYA Biosciences股票行情,IDEAYA Biosciences股价,IDEAYA Biosciences股市,IDEAYA Biosciences股票价格,IDEAYA Biosciences股票交易,IDEAYA Biosciences股票购买,IDEAYA Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"IDEAYA Biosciences(IDYA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供IDEAYA Biosciences(IDYA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}